TrialSignal
Clinical trial intelligence report
Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04123392
Status
UNKNOWN
Phase
PHASE2
Sponsor
Nanfang Hospital, Southern Medical University
Executive brief
Investment-Ready Snapshot
Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation is a PHASE2 clinical asset sponsored by Nanfang Hospital, Southern Medical University in TP53, Myeloid Tumors, Conditioning, Allogeneic Hematopoietic Stem Cell Transplantation. SEO and diligence focus: Decitabine, Busulfan (BU), Cyclophosphamide (CY), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04123392
Indication
TP53
Modality
small molecule
Target
Decitabine, Busulfan (BU), Cyclophosphamide (CY)
Intervention
Decitabine, Busulfan (BU), Cyclophosphamide (CY)
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.